Argent BioPharma Limited

RGT.L · LSE
Analyze with AI
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Operating Activities
Net Income£0£0£0£0
Dep. & Amort.£0£0£0£0
Deferred Tax£0£0£0£0
Stock-Based Comp.£0£0£0£0
Change in WC£0£0£0£0
Other Non-Cash-£7,737£0£0£0
Operating Cash Flow-£7,737£0£0£0
Investing Activities
PP&E Inv.-£140-£190-£2,693-£3,327
Net Acquisitions£0£0-£5-£373
Inv. Purchases£0£0£0£0
Inv. Sales/Matur.£0£0£0£303
Other Inv. Act.£0£796£1,586£1,904
Investing Cash Flow-£140£606-£1,111-£1,494
Financing Activities
Debt Repay.£0£7,164£61£5,750
Stock Issued£15,701£3,087£10,703£12,760
Stock Repurch.£0-£318-£764-£1,203
Dividends Paid£0£0£0£0
Other Fin. Act.-£7,049-£201-£263-£256
Financing Cash Flow£8,055£9,732£9,738£17,051
Forex Effect-£1£9-£15-£8
Net Chg. in Cash£463-£1,647-£3,547£3,560
Supplemental Information
Beg. Cash£240£1,886£5,433£1,873
End Cash£703£240£1,886£5,433
Free Cash Flow-£14,402-£12,185-£14,851-£15,317